Menopause treatment linked to longer survival in breast cancer patients
A recent study in the U.S. has found that estrogen creams, commonly used to alleviate menopause symptoms, are not only safe for older women diagnosed with breast cancer, but may also correlate with increased survival rates.
The research, which was presented at the ASCO meeting, indicated that postmenopausal breast cancer survivors who used hormone creams experienced a reduced risk of disease progression, recurrence, or death. These findings challenge previous concerns that the creams could stimulate the growth of breast cancer cells that rely on hormones.
Vaginal estrogen creams are frequently used to treat menopause symptoms such as vaginal dryness, discomfort and pain during intercourse. As a result of previous concerns, many breast cancer survivors avoid these treatments.
Researchers reviewed national database records on 18,620 female breast cancer patients aged 65 and older who were diagnosed between 2010-2017, including 800 who used vaginal estrogen creams.
After accounting for patients' race, cancer stage, treatments and other factors, the researchers saw a statistically significant increase in overall survival among patients who used vaginal estrogen.
The cream users also had a significant increase in breast cancer-specific survival, the interval from diagnosis to death from breast cancer.
On average, estrogen cream users had a 47 per cent lower risk of dying from breast cancer and a 44 per cent lower risk of death from any cause during the study period, compared to non-users.
Even in patients whose tumours were known to use hormones for growth, estrogen cream use was associated with a 38 per cent lower risk of death from any cause.
Main symptoms of breast cancer in women
NHS
Estrogen cream users with hormone-positive breast cancer also had a lower risk of death from breast cancer, but that difference was not statistically significant.
Use of the creams for more than seven years appeared to confer an additional survival benefit.
'These findings add to a rising contemporary paradigm shift that local hormone therapy is not associated with increased risk to overall or breast cancer-specific survival, which has important clinical implications,' the researchers said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
18 minutes ago
- The Guardian
Alzheimer's blood test can spot people with early symptoms, study suggests
A new blood test for Alzheimer's disease can accurately detect people with early symptoms, research suggests. Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia by examining two proteins in blood plasma. The proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque buildup, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the journal Alzheimer's and Dementia, said the test was as good as more invasive tests in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who showed no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting,' he added. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline, though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US. We hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multimillion-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the National Health Service by 2029. Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40 and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'
Sky News
4 hours ago
- Sky News
Blood test for Alzheimer's disease is highly accurate, researchers say
Researchers say a new blood test for Alzheimer's disease has been shown to be highly accurate in detecting people with early symptoms. Scientists looked for two proteins - amyloid beta 42/40 and p-tau217 - and found the test was 95% accurate in identifying patients with existing cognitive impairment linked to the condition. The US study involved 509 patients in an outpatient memory clinic in Florida and was published in the medical journal Alzheimer's and Dementia. The test, which has already been approved by the US regulator, was also 82% accurate for specificity, which means it could rule out people without dementia. Dr Gregg Day, who led the study, said the test was as good as existing, but more invasive, tests. He said the next step was to extend the test to a wider range of patients, including those with early Alzheimer's who do not have any cognitive symptoms. Scientists say the two proteins, which they have identified in blood plasma, are associated with the buildup of amyloid plaques. Amyloid protein can be found in our brains, but in Alzheimer's disease, amyloid sticks together and forms abnormal deposits, which are thought to be toxic to brain cells. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results "suggest this test is very accurate". "Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before," he added. In the UK, the Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. 1:09 Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Julia Dudley, head of research at Alzheimer's Research UK, said: "We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal." She said the studies like the Blood Biomarker Challenge are a "crucial part of making diagnosis easier and faster, which will bring us closer to a cure". "The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK," she added.
Daily Mail
5 hours ago
- Daily Mail
ANDREW NEIL: Like a clown running into a minefield, Musk threw caution to the wind, but he's right - Trump's 'big beautiful bill' IS a 'disgusting abomination'
Well, that didn't take long. When I boarded a flight for New York on Thursday, Donald Trump and Elon Musk were still sticking to the script: though the dizzy days of their bromance might be over, the separation was amicable. The most powerful man in the world and the richest even staged a chummy farewell in the Oval Office last week to underline the point. Yet by the time I'd landed at JFK just over seven hours later, Washington's version of Krakatoa had erupted.
